| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6150337 | BAUSCH | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
Nov, 2017
(6 years ago) | |
Virazole is owned by Bausch.
Virazole contains Ribavirin.
Virazole has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Virazole are:
- US6150337
Virazole was authorised for market use on 31 December, 1985.
Virazole is available in for solution;inhalation dosage forms.
Virazole can be used as use of ribavirin to increase type 1 cytokine response and suppress type 2 cytokine resp0nse to lymphocytes, including methods that take advantage of such modulation to treat infections and infestations.
The generics of Virazole are possible to be released after 21 November, 2017.
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 31 December, 1985
Treatment: Use of ribavirin to increase type 1 cytokine response and suppress type 2 cytokine resp0nse to lymphocytes, including methods that take advantage of such modulation to treat infections and infestation...
Dosage: FOR SOLUTION;INHALATION
VIRAZOLE family patents
